ロード中...
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors
EGFR is an oncogene with a high frequency of activating mutations in nonsmall cell lung cancer (NSCLC). EGFR inhibitors have been FDA-approved for NSCLC and have shown efficacy in patients with certain EGFR mutations. However, only 9% to 26% of these patients achieve objective responses. In our stud...
保存先:
| 出版年: | Int J Cancer |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7880578/ https://ncbi.nlm.nih.gov/pubmed/32406930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33053 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|